Radiation therapy

Where the papers sit

42 papers from the last 6 months study radiation therapy directly · updated from PubMed 12 Oct 2026

• Radiotherapy Across Solid Tumors

  Radiotherapy is being positioned differently across solid tumors, from organ-preserving treatment and postoperative control to salvage therapy and multimodal disease management. Comparisons include transoral surgery, chemotherapy, immunotherapy, hyperthermia, and radiation timing across head and neck, esophageal, melanoma, sarcoma, brain, liver, and thoracic cancers. Outcomes repeatedly center on local control, progression-free survival, overall survival, failure patterns, and toxicity. Evidence remains disease-specific, with molecular subtype, resection status, age, and treatment sequence shaping benefit.

  14 papers · 33.3%

• Radiation and Tumor Immunity

  Radiotherapy is increasingly being used to reshape the tumor immune microenvironment rather than act alone. Studies implicate CD200-positive macrophages, radiation-induced chemokines, T-cell remodeling, angiogenesis, and oxygen-driven heterogeneity in response or resistance. PD-1 blockade, GSDME-mediated pyroptosis, UFMylation inhibition, and molecular decoys are being combined with radiation to strengthen antitumor immunity. The field is moving toward spatially and molecularly selected radioimmunotherapy, but immune suppression remains a major barrier.

  10 papers · 23.8%

• Radiotherapy Toxicity and Survivorship

  Breast radiotherapy research is balancing survival benefit against late effects, reconstruction constraints, second primary lung cancer, and patient-reported symptoms. Age-dependent benefit after breast-conserving surgery supports more selective treatment decisions, while implant type, placement, and dose affect reconstruction outcomes. Weakness, dizziness, fall risk, lymphocyte apoptosis, ototoxicity, and psychological burden recur as survivorship concerns across cancer treatment. Better supportive care and real-time treatment delivery are being pursued alongside oncologic control.

  8 papers · 19%

• Radiotherapy Planning and Outcomes

  Anatomy-adaptive planning is becoming central to radiotherapy, using MRI, coronary habitats, and disease-specific margins to shape treatment volumes. Glioma studies emphasize interfraction MRI adaptation, while breast treatment questions whether nodal and chest-wall targets need equal margins. High-dose treatment is also being tested alongside long-term androgen deprivation in high-risk prostate cancer. The recurring endpoints are target coverage, cardiac sparing, progression-free survival, and local control.

  5 papers · 11.9%

• Personalized Lung Cancer Radiosensitization

  Personalized combinations are replacing uniform radiosensitization strategies in non-small cell lung cancer. Multi-omics and virtual-tumor models aim to identify patients most likely to benefit from adaptive carbon-ion radiotherapy or specific drug combinations. PD-L1-targeted small molecules, METTL14/Wnt9a/β-catenin inhibitors, and engineered nanoparticles pair direct tumor effects with radiation, chemotherapy, immunotherapy, or imaging. Durable survival benefit and clinically validated patient selection remain open questions.

  5 papers · 11.9%